We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
Comen Medical

Download Mobile App





Rapid Molecular Diagnostic Platform Sends Precise COVID-19 RNA Results to Smartphone in Minutes

By HospiMedica International staff writers
Posted on 05 Mar 2021
Print article
Image: Rapid Molecular Diagnostic Platform Sends Precise COVID-19 RNA Results to Smartphone in Minutes (Photo courtesy of Purdue University/Chris Adam)
Image: Rapid Molecular Diagnostic Platform Sends Precise COVID-19 RNA Results to Smartphone in Minutes (Photo courtesy of Purdue University/Chris Adam)
An all new technology can detect COVID-19 RNA in saliva through newly developed electronic nanosensors, which significantly reduces error rates associated with chemical-based home tests.

IdentifySensors Biologics (Cleveland, OH, USA), a nanosensor technology firm which has developed the rapid diagnostic platform for detecting pathogens, including SARS-CoV-2, has now joined the SMART Film Consortium, led by the Birck Nanotechnology Center at Purdue University (West Lafayette, IN, USA) that seeks to develop the first foundry dedicated to low-cost non-silicon printed sensors.

Unlike other molecular tests for COVID-19, the rapid molecular diagnostic platform automatically transmits test results to consumer smartphones and to the proper health agencies in minutes. The platform technology can be easily modified to also detect influenza, Zika, dengue, HIV/AIDS, hepatitis C, Lyme disease, mumps, measles, chickenpox and methicillin-resistant staphylococcus Aureus (MRSA) and foodborne pathogens.

"By joining the SMART Film Consortium, IdentifySensors Biologics has positioned itself in a significantly strategic vantage point where it is able to tap into a wide array of printing and scalable manufacturing resources in the Birck Nanotechnology Center to greatly accelerate the development of their COVID-19 sensor," said Thomas Sors, assistant director of the Purdue Institute of Inflammation, Immunology and Infectious Disease.

Related Links:
IdentifySensors Biologics
Purdue Research Foundation



Print article

Channels

Business

view channel
Image: Respicardia’s remedē System (Photo courtesy of Respicardia, Inc.)

Zoll Medical Acquires CSA Systems Manufacturer Respicardia

ZOLL Medical Corporation (Chelmsford, MA, USA), an Asahi Kasei company, has acquired Respicardia, Inc. (Minnetonka, MN, USA), a provider of novel implantable neurostimulators for the treatment of moderate... Read more
Copyright © 2000-2021 Globetech Media. All rights reserved.